Literature DB >> 20188589

Arterial patency after repeated hepatic artery bland particle embolization.

Joseph P Erinjeri1, Husam M Salhab, Anne M Covey, George I Getrajdman, Karen T Brown.   

Abstract

PURPOSE: To evaluate hepatic arterial patency after serial bland particle embolization procedures in patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: All patients with HCC who underwent five or more hepatic artery bland embolization procedures with permanent particulate and spherical embolic agents between September 1996 and December 2007 were retrospectively reviewed. Data analyzed included patient demographics, vessels embolized, embolic agent used, and duration of arterial patency.
RESULTS: Forty-three patients were identified who underwent five or more bland embolization procedures in the same arterial distribution. Of the 43 patients examined, 83% (n = 36) showed no change in the hepatic arterial tree after repeated bland embolization (mean treatment period of 48 months +/- 23). Six patients (13%) exhibited occlusion of a fifth-order or more distal vessel after an average of 5 embolizations +/- 2 over a period of 34 months +/- 27. A single case of vascular occlusion of a fourth-order vessel was observed after five embolizations over a period of 52 months.
CONCLUSIONS: Repeated bland embolization of the hepatic arteries in HCC preserves patency of the hepatic arterial vasculature despite the fact that embolization is carried out to complete stasis. Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188589      PMCID: PMC6615059          DOI: 10.1016/j.jvir.2009.12.390

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  9 in total

1.  [Transarterial ablation of hepatocellular carcinoma. Status and developments].

Authors:  B A Radeleff; U Stampfl; C M Sommer; N Bellemann; K Hoffmann; T Ganten; R Ehehalt; H U Kauczor
Journal:  Radiologe       Date:  2012-01       Impact factor: 0.635

2.  Intermediate hepatocellular carcinoma: the role of transarterial therapy.

Authors:  Fabrizio Chegai; Antonio Orlacchio; Stefano Merolla; Serena Monti; Lorenzo Mannelli
Journal:  Hepat Oncol       Date:  2015-10

3.  Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Silvia Roma; Stefano Merolla; Alessandra Bosa; Simona Francioso
Journal:  Radiol Med       Date:  2019-10-03       Impact factor: 3.469

Review 4.  Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.

Authors:  Alan Alper Sag; Fatih Selcukbiricik; Nil Molinas Mandel
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

5.  Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes.

Authors:  Peachy Mae Piana; Voichita Bar; Laura Doyle; Rani Anne; Takami Sato; David J Eschelman; Jeffrey W McCann; Carin F Gonsalves; Daniel B Brown
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

6.  Successful control of liver metastases from pancreatic solid-pseudopapillary neoplasm (SPN) using hepatic arterial embolization.

Authors:  Elena G Violari; Lynn A Brody; Anne M Covey; Joseph P Erinjeri; George I Getrajdman; Constantinos T Sofocleous; Diane L Reidy; William R Jarnagin; Karen T Brown
Journal:  Cardiovasc Intervent Radiol       Date:  2014-05-06       Impact factor: 2.797

7.  Evaluation of arterial impairment after experimental gelatin sponge embolization in a rabbit renal model.

Authors:  Jung Suk Oh; Hae Giu Lee; Ho Jong Chun; Byung Gil Choi; Yeong Jin Choi
Journal:  Korean J Radiol       Date:  2015-01-09       Impact factor: 3.500

8.  Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study.

Authors:  Katerina Malagari; Maria Pomoni; Hippokratis Moschouris; Alexios Kelekis; Angelos Charokopakis; Evanthia Bouma; Themistoklis Spyridopoulos; Achilles Chatziioannou; Vlasios Sotirchos; Theodoros Karampelas; Constantin Tamvakopoulos; Dimitrios Filippiadis; Enangelos Karagiannis; Athanasios Marinis; John Koskinas; Dimitrios A Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2013-11-22       Impact factor: 2.740

Review 9.  Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Bela Kis; Ghassan El-Haddad; Rahul A Sheth; Nainesh S Parikh; Suvranu Ganguli; Paul B Shyn; Junsung Choi; Karen T Brown
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.